Market Size in 2023 | Market Forecast in 2032 | CAGR (in %) | Base Year |
---|---|---|---|
USD 938.65 Million | USD 2788.46 Million | 12.86% | 2023 |
The global Mycoplasma Testing market size was worth around USD 12.867 million in 2023 and is predicted to grow to around USD 2788.46 million by 2032 with a compound annual growth rate (CAGR) of roughly 12.86% between 2024 and 2032.
The study provides historical data from 2018 to 2022 along with a forecast from 2024 to 2032 based on revenue (USD million). The report covers a forecast and an analysis of the Mycoplasma Testing market on a global and regional level.
Mycoplasmas are the simplest self-replicating and smallest bacteria belonging to the mollicute genus. Myoplasmas are naturally resistant to antibiotics as they lack cell wall structure around their cell membranes. Due to the small genome size, they cannot synthesize amino acids, nucleic acids, and cell walls,s and thus they exist as parasites in host organisms like animals, plants, humans, and insects. Mycoplasma testing is an important process at various phases of biopharmaceutical and pharmaceutical product development including cell banks, raw materials, unprocessed bulk harvest materials, viral seed stocks, and final products. Mycoplasma contamination often goes undetected as they do not cause constantly noticeable alterations like changes in turbidity, pH change, etc.
The demand for the mycoplasma testing market is driven by strong growth witnessed by the pharmaceutical and biopharmaceutical industry across the globe. Also, cell culture contamination with mycoplasma is a major concern. Increasing investments in life science research, the need to control cell culture contamination, and the surge in R&D expenditure are factors that boost market growth. The presence of large and well-established market players may act as a barrier for new entrants. Stringent regulatory requirements, time-consuming approval procedures, lack of skilled professionals, and a high degree of consolidation may act as restraining factors for market growth. Increasing preference for outsourcing services for mycoplasma testing is expected to bring new growth opportunities for market players in mycoplasma testing.
The study provides a crucial view on mycoplasma testing by segmenting the market based on product, technique, application, end-user, and region. All the segments of mycoplasma testing market have been analyzed based on present and future trends and the market is estimated from 2024 to 2032.
Based on product, the global mycoplasma testing market is bifurcated into instruments, services, and kits & reagents. The kits and reagents segment is sub-segmented into standards & controls, stains, elimination kits & reagents, nucleic acid detection, PCR assay, and other kits & reagents. The kits and reagents segment held the largest market share in 2018. Continuous and frequent use of kits and reagents attribute to strong commercial sales and thus large market share. The services segment is expected to exhibit the highest market growth in the coming years.
Based on techniques market is segmented into enzymatic methods, microbial culture techniques, DNA staining, indirect assay, direct assay, ELISA, and PCR. The PCR technique segment held the largest market share in 2023. Speed, accuracy, and flexibility of PCR technique in life science research have led to greater adoption and thus attributes to the largest market share.
The application segment is divided into include end of production cell testing, virus testing, cell line testing, and other applications. The largest application segment for the mycoplasma testing market in 2023 was cell line testing. Increasing drug development activities by major pharmaceutical and biopharmaceutical companies have resulted in greater adoption of mycoplasma which is also expected to register the highest growth over the forecast period. The surge in the use of cell line testing for biopharmaceutical production and research application drive the demand for mycoplasma testing in the cell line.
Research institutes, pharmaceutical, and biotechnology companies, cell banks, contract research organizations (CROs), and others are end users of the market. Pharmaceutical and biotechnology companies accounted for the largest market share in 2023. Increasing R&D investments and a surge in biomolecule development attribute to the large market share.
Report Attributes | Report Details |
---|---|
Report Name | Mycoplasma Testing Market |
Market Size in 2023 | USD 938.65 Million |
Market Forecast in 2032 | USD 2788.46 Million |
Growth Rate | CAGR of 12.86% |
Number of Pages | 110 |
Key Companies Covered | Agilent Technologies, PromoCell GmbH, Eurofins Scientific, SGS S.A., Roche Diagnostics, Merck KGaA, Lonza Group Ltd., Charles River Laboratories International Inc., Thermo Fisher Scientific Inc., American Type Culture Collection, and among others. |
Segments Covered | By Product, By Technique, By Application, By End User and By Region |
Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA) |
Base Year | 2023 |
Historical Year | 2018 to 2022 |
Forecast Year | 2024 - 2032 |
Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
North America dominated the global mycoplasma testing market in 2023. The developed biopharmaceutical industry, presence of major biopharmaceutical manufacturers, developed R&D infrastructure, and increasing investments are factors driving the market growth in this region. In terms of revenue share, Europe was the second largest regional market. The presence of developed infrastructure, increasing demand for biopharmaceutical research, and government initiatives to support R&D are some of the factors that boost the market growth in this region. Latin America is expected to exhibit noticeable growth over the forecast period. Asia Pacific region will exhibit rapid growth in the mycoplasma testing market in the years to come. The focus of contract research organizations on offering outsourcing services to capture growth opportunities in developing nations in the Asia Pacific, the surge in biopharmaceutical and pharmaceutical research, and government initiatives to biopharmaceutical research are factors promoting mycoplasma testing market growth in the Asia Pacific. Lack of funds and developed infrastructure may attribute to sluggish growth in the Middle East and Africa.
Global Mycoplasma Testing Market: By Product
Global Mycoplasma Testing Market: By Technique
Global Mycoplasma Testing Market: By Application
Global Mycoplasma Testing Market: By End User
Global Mycoplasma Testing Market: By Region
FrequentlyAsked Questions
Mycoplasmas are the simplest self-replicating and smallest bacteria belonging to the mollicute genus. Myoplasmas are naturally resistant to antibiotics as they lack cell wall structure around their cell membranes.
According to study, the Mycoplasma Testing Market size was worth around USD 12.867 million in 2023 and is predicted to grow to around USD 2788.46 million by 2032.
The CAGR value of Mycoplasma Testing Market is expected to be around 12.86% during 2024-2032.
North America has been leading the Mycoplasma Testing Market and is anticipated to continue on the dominant position in the years to come.
The Mycoplasma Testing Market is led by players like Agilent Technologies, PromoCell GmbH, Eurofins Scientific, SGS S.A., Roche Diagnostics, Merck KGaA, Lonza Group Ltd., Charles River Laboratories International Inc., Thermo Fisher Scientific Inc., American Type Culture Collection, and among others.
RelatedNews
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed